EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation (Q44235598)

1 December 2017

title

EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation (English)

1 reference

1 December 2017

main subject

multiple drug resistance

1 reference

1 reference

A Davidson

1

1 reference

1 December 2017

Gina Dick

series ordinal

2

1 reference

1 December 2017

K Pritchard-Jones

series ordinal

3

1 reference

1 December 2017

R Pinkerton

series ordinal

4

1 reference

1 December 2017

publication date

1 December 2002

1 reference

European Journal of Cancer

1 December 2017

published in

1 reference

1 December 2017

volume

38

1 reference

1 December 2017

issue

18

1 reference

1 December 2017

page(s)

2422-2427

1 reference

The role of megatherapy with autologous bone marrow rescue in solid tumours of childhood.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Etoposide for the treatment of paediatric tumours: what is the best way to give it?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900493-8

7 January 2021

10.1016/S0959-8049(02)00493-8

Identifiers

DOI

1 reference

1 December 2017

1 reference